Peripheral blood lymphocyte proviral DNA predicts neurocognitive impairment in clade C HIV

Vurayai Ruhanya1,2 · Graeme Brendon Jacobs1 · George Nyandoro2 · Robert H. Paul3 · John A. Joska4 · Soraya Seedat5 · Richard Helmuth Glashoff6,7 · Susan Engelbrecht1,7

Received: 30 April 2020 / Revised: 12 June 2020 / Accepted: 6 July 2020 / Published online: 31 July 2020 ● The Author(s) 2020

Abstract
It is not known if proviral DNA in the periphery corresponds to cognitive status in clade C as it does in clade B and recombinant forms. A cross-sectional study was conducted on participants investigated for HIV-associated neurocognitive impairment in South Africa. HIV-1 proviral DNA was quantified using a PCR assay targeting a highly conserved HIV-1 LTR-gag region. Fifty-four (36.7%) participants were cognitively impaired and 93 (63.3%) were not impaired. Forty-three (79.6%) of the cognitively impaired participants were female and 11 (20.4%) were male. There was no significant age difference between cognitively impaired and unimpaired participants \( (p = 0.42) \). HIV-1 DNA in cognitively impaired PLWH was significantly higher than in cognitively normal individuals \( (p = .016) \). Considering impaired participants, lymphocyte HIV-1 DNA was significantly higher in males than females \( (p = 0.02) \). There was a modest positive correlation between lymphocyte HIV-1 DNA and global deficit scores \( (GDS) \); \( r = 0.176; p = 0.03 \). The two measures of viral load, lymphocyte HIV-1 DNA copies/million and plasma RNA copies/ml, were positively correlated \( (r = 0.39; p < .001) \). After adjusting for other covariates, age, sex, treatment status, and the interactions between impairment and treatment, the multivariate regression showed association between proviral load and neurocognitive impairment; omega effect size was 0.04, \( p \) value = 0.010. The burden of HIV-1 peripheral blood lymphocyte proviral DNA corresponds to neurocognitive impairment among individuals infected with clade C disease. Therefore, therapeutic strategies to reduce the HIV-1 proviral DNA reservoir in lymphocytes may improve neurocognitive outcomes in PLWH.

Keywords HIV-1 proviral DNA · HAND · Lymphocytes

Introduction
HIV-1-associated neurocognitive disorders (HAND) remain an important clinical concern. HAND affects 40–70% of HIV-1-infected patients (Williams et al. 2014; Yusuf et al. 2017), despite immune reconstitution and viral suppression because of combination antiretroviral therapy (cART) (Cysique et al. 2015). The exact mechanism of HAND pathogenesis is not known, but it is thought to be a complex interaction of factors including cellular targets, viral factors, and the immune response (Saylor et al. 2016; Carroll and Brew 2017; Ruhanya et al. 2017). Evidence from experimental models and human studies show that HAND pathogenesis involves a seeding of peripheral HIV-1 into the central...
nervous system (CNS) (Price et al. 2007). HIV RNA has been detected in CSF within 8 days of infection, and immune activation is associated with neuropathogenesis (Hellmuth et al. 2015; Valcour et al. 2012). Residual viremia and HIV-1 DNA reservoirs in the periphery are linked to activation-induced neuronal damage (Cysique et al. 2015; Valcour et al. 2012) as well as chronic immune activation from macrophages, glial cells, and astrocytes (Hong and Banks 2015).

Brain invasion by HIV can develop into HIV-associated encephalitis (HIVE) which is comprised of microglial nodules, activated resident microglia, multinucleated giant cells, and infiltration by blood-derived macrophages (Williams et al. 2014; Valcour et al. 2012; Hong and Banks 2015). Clinically, people with CNS HIV-1 infection present with a spectrum of cognitive symptoms referred to as HIV-associated neurocognitive disorders (HAND) (Valcour et al. 2012). The introduction of cART has significantly reduced severe forms of HAND, although more subtle clinical presentations, which can pose difficulties for detection and monitoring, are still pervasive. Therefore, HIV-specific biomarkers are needed to assist in devising diagnostic and therapeutic approaches.

Elevated levels of HIV-1 DNA in peripheral blood mononuclear cells (PBMCs) contribute to the expression of HAND (Kamat et al. 2012; Shiramizu et al. 2009). Although evidence has demonstrated a correlation between HIV-1 DNA in PBMCs and the severity of HAND, most studies have been conducted on HIV-1 subtype B, the dominant strain in North America and Europe (Valcour et al. 2010). Data are lacking regarding HAND and subtype C, which is predominant in Southern Africa. We do not know if proviral DNA in the periphery corresponds to cognitive status in clade C as it does in clade B and recombinant forms (Valcour et al. 2013). Additionally, most studies in clade B cohorts have utilized unfractionated PBMCs and monocytes (Shiramizu et al. 2009; Kamat et al. 2012). The aim of this study was to determine whether peripheral monocyte-depleted CD14- lymphocytes correspond to HAND. We hypothesized that proviral HIV-1 DNA levels would be higher in neurocognitively impaired than in non-impaired individuals infected with HIV-1 subtype C.

Material and methods

Study design and patient samples

A cross-sectional study was conducted on a cohort of 147 HIV-1 positive individuals recruited from primary care HIV-1 clinics in Cape Town, South Africa. Participants were enrolled in a parent study focused on neuropsychological and brain imaging signatures in HIV-1 subtype C (Valcour et al. 2013; Paul et al. 2014).

Neuropsychological evaluation

A battery of cognitive tests sensitive to HIV-1 was administered to all participants as described by Paul et al. 2014. Briefly, the tests were administered to assess learning, executive functions, and visuospatial and psychomotor speed. Learning was assessed as described previously (Paul et al. 2017; Valcour et al. 2013; Benedict et al. 1996). T-scores for individual cognitive tests were averaged to generate a global T-score and a global deficit score (GDS); GDS > 0.5 defined neurocognitive impairment as described elsewhere (Heaps-Woodruff et al. 2017; Jumare et al. 2017).

Cell subset separation

Whole blood samples were collected and PBMCs separated by Ficoll gradient separation (Ficoll-Histopaque, Pharmacia, Uppsala, Sweden). CD14+ monocytes were separated by magnetic cell sorting (MACS, Miltenyi Biotec GmbH, and Bergisch Gladbach, Germany) and the peripheral blood lymphocytes (CD14-) were recovered from negative fraction of the CD14+ monocytes. The total CD3+, CD4+, and CD45+ count and percentages were determined using standardized T cell subset protocols (BDMultiset) and flow cytometry analysis (BD FACS Calibur).

Quantification of proviral DNA in peripheral lymphocytes

HIV-1 DNA was extracted from monocyte depleted lymphocytes (CD14-) using the QIAamp Blood Mini extraction kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Nine specimens without complete clinical-demographic information were excluded. The quantity and purity of extracted HIV-1 DNA was determined by NanoDrop® ND-1000, (Thermo Fisher Scientific, MA, USA) spectrophotometer readings.

Quantification of total HIV-1 DNA proviral levels were determined according to the protocol described by Malnati et al. (Malnati et al. 2008), using a quantitative real-time PCR (qPCR) that targets the conserved HIV-1 LTR-gag region. Calibration standards for quantifying proviral DNA were made using the subtype C infectious plasmid clone, pMJ4, obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, and NIH: (Ndung’u et al. 2001). Briefly, the concentration of the pMJ4 plasmid DNA in nanograms/microliter (ng/μl) was obtained using Nanodrop ND-1000 spectrophotometer. Plasmid DNA copy numbers per microliter (copies/μl) were then determined, using an online DNA copy calculator, on the assumption that the average weight of a base pair is 650 Da, using the following formula: mass × 6.023 × 1023 divided by 12,833 (length) in base pairs (bp) × 1 × 109 × 660 (1 Prediger 2008). From this initial
concentration (copies/μl), tenfold serial dilution stocks were made, to construct a standard curve. The qPCR for the standard curve and master mix were performed using iTaq super mix (Bio-Rad, California, USA) and HIV-1 specific primers and probes, described previously by Malnati et al. 2008.

The standards were run on a CFX 96 thermocycler using Bio-Rad CFX Manager 3.1 to plot the standard curve. Proviral HIV-1 DNA copies from samples were calculated from this plot using Ct (cycle threshold) values. HIV-1 cell-associated DNA (CAD) was normalized to cell input by quantification of the CCR-5 genome copies per sample. The calibration curve for quantifying genomic DNA was constructed using the CCR5 plasmid, which was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, and NIH: pcCCR5 (Cat#3325) (Morgenstern and Land 1990). Briefly, the concentration of CCR5 plasmid DNA was obtained using the Nanodrop ND-1000 spectrophotometer and plasmid DNA copies/μl were obtained using the online copy calculator (Prediger 2008). Sample copy numbers for genomic DNA input were then calculated from this curve, using the test sample’s Ct by the Bio-Rad CFX manager version 3.1 (Bio-Rad, California, USA).

**Statistical analysis**

Data analyses were completed using Stata version 13.1 (StataCorp, College Station, Texas, USA). HIV DNAs in lymphocytes mean differences between impaired and unimpaired were assessed using independent t test and the Cohen’s d effect size was established to quantify the extend of the difference in proviral DNA. Furthermore, covariates (age, sex, treatment status, and interaction of impairment and treatment status) were adjusted for further validation of the observed effects using multiple regression modeling. Pearson correlation coefficients assessed the association between HIV-1 peripheral blood lymphocyte DNA and neurocognitive impairment. The same test was also used to assess the association between neurocognitive impairment and clinical variables, such as plasma RNA viral load, CD4+ T cell count, monocyte count, and CD4/CD8 ratio. Statistical significance was determined as p value < 0.05.

**Results**

**Clinical and demographic characteristics**

Fifty-four (36.7%) participants were cognitively impaired and 93 (63.3%) were not impaired; thus the proportion of impaired participants was less than those not impaired (p = 0.0017). More females were impaired; Forty-three (79.6%) of the cognitively impaired participants were female and 11 (20.4%) were male, p < 0.001. There was no significant age difference between cognitively impaired and unimpaired participants (p = 0.42). Twenty-seven (17.8%) of the participants had initiated cART for less than 4 weeks and 125 (82.2%) had not initiated treatment, at the time of the study. The T-helper-suppressor ratio was higher in cognitively normal patients than cognitively impaired patients, although the difference was not significant (p = 0.33). CD14 enriched monocytes were higher in cognitively impaired patients than normal participants, although this was not statistically significant (p = 0.21). Table 1 summarizes the clinical and demographic characteristics of the participants in the cohort.

**CD14: HIV DNA qPCR**

We used a sensitive qPCR with high efficiency of more than 90% for both the normalizer CCR5 and HIV-1 with all the coefficient of determination, R² greater than 0.99 for both assays. The limit of detection for the CCR5 assay was eight copies and that for HIV DNA assay was one copy per reaction.

Figure 1 shows standard curve for HIV starting from 3 to $2.5 \times 10^4$ copies using the pMJ4 standards. The average sample input DNA quantity per reaction was 220.2 ng from which an average of 88,579 CCR5 genome copies was quantified. Figure 2 shows CCR5 standard curve with quantities ranging from 8 copies to $8 \times 10^5$ copies.

The mean peripheral blood lymphocytes HIV-1 DNA for cognitively impaired PLWH was 419.76 copies per million cells compared with 240.38 in unimpaired cases. HIV-1 DNA in cognitively impaired PLWH was significantly higher than in cognitively normal individuals (p = 0.016). The

| Clinical & demographic variables (Mean, SD) | Not impaired (n = 93) | Impaired (n = 54) | p value |
|-------------------------------------------|----------------------|------------------|---------|
| Age                                       | 31.5 (5.55)          | 31.53 (4.70)     | 0.42    |
| CD4 T-lymphocytes                          | 243.36 (179.15)      | 221.56 (158.34)  | 0.77    |
| CD14+                                     | 13.99 (0.62)         | 14.12 (0.62)     | 0.10    |
| Plasma RNA viral load                      | 96,973.29 (242238)   | 203,139 (545673) | 0.05    |
| CD45                                      | 1502.04 (702.03)     | 1515.69 (690.73) | 0.45    |
| CD4:CD8 ratio                              | 0.31 (0.21)          | 0.28 (0.18)      | 0.33    |

Table 1 Clinical and demographic characteristics of the cohort
Cohen’s d effect size was $-0.42$, lower in the unimpaired compared with impaired group with 95% confidence interval (CI): $-0.75$ to $-0.08$. After adjusting for other covariates, age, sex, treatment status, and the interactions between impairment and treatment, the regression omega effect size was 0.04, p value = 0.010; see Table 2. Figure 3 illustrates the differences in HIV-1 DNA in impaired and unimpaired participants.

There was a modest positive correlation between lymphocyte HIV-1 DNA and global deficit scores (GDS) $r = 0.176$; p = 0.03). The two measures of viral load, lymphocyte HIV-1 DNA copies/million and plasma RNA copies/ml, were positively correlated ($r = 0.39$; p < 0.001). Considering impaired participants, proviral HIV-1 DNA was significantly higher in males than females (p = 0.034). There was no association between GDS and absolute CD4+ count or plasma viral load. However, there were significant differences in plasma viral load (p < 0.001) and CD4+ absolute count (p = 0.02) between cART naïve and participants initiating treatment. Other parameters (CD4:CD8 ratio, CD14+ cells, absolute CD45 count) did not differ by treatment status (p = 0.28, 0.1698, and 0.24, respectively). The normalizer, CCR5, did not differ by neurocognitive status (p = 0.21). We undertook further analysis to assess if there was an association between domain-specific cognitive impairments (e.g., learning, mental control, recall, and others that are used to calculate the GDS) and proviral HIV-1 DNA. We found that Hopkins Verbal Learning Test score (hvlt learning) (p = 0.049) and Wechsler Adult Intelligence Scale score (WAIS III symbol search) (p = 0.035) were significantly reduced with increased proviral HIV-1 DNA, when adjusted for sex, age, and treatment status. Compared with females, males had significantly lower Wechsler memory scale (WMS mental control) (p = 0.007), WAIS III digit symbol (p = 0.009), and WAIS III symbol search (p = 0.033) test scores; see Table 3.
Table 2  Proviral HIV-1DNA (copies/million cells) Mean differences between impaired and non-impaired groups

| Group   | Obs | Mean   | Std. Err. | Std. Dev. | [95% Conf. Interval] |
|---------|-----|--------|-----------|-----------|---------------------|
| Normal  | 93  | 240.3763 | 29.31945  | 282.7466  | 182.1454  298.6073  |
| Impaired| 54  | 419.7593 | 82.8949   | 609.1506  | 253.4932  586.0254  |
| Combined| 147 | 306.2721 | 36.19747  | 438.871   | 234.7334  377.8108  |
| Diff    |     | −179.3829 | 73.8567   | −325.3578 | 33.40798  |
| diff = mean(normal) - mean(impaired) |
| Ho: diff = 0  Degrees of freedom | 145 |
| Ha: diff < 0  Pr(T < t) = 0.0082 |  |
| Pr(T > t) = 0.0164 |
| Effect Size  Estimate [95% Conf. Interval] |
| Cohen’s d | −0.415538 | −0.7535504 | −0.0761216 |
| test hivdnacopiespermillion, by(sex) |
| Group   | Obs | Mean   | Std. Err. | Std. Dev. | [95% Conf. Interval] |
|---------|-----|--------|-----------|-----------|---------------------|
| Female  | 121 | 276.1901 | 32.75203  | 360.2723  | 211.3433  341.0368  |
| Male    | 24  | 455.75  | 146.7344  | 718.849   | 152.2067  759.2933  |
| Combined| 145 | 305.9103 | 36.68911  | 441.7954  | 233.3916  378.4291  |
| Diff    |     | −179.5599 | 97.92037  | −373.1184 | 13.99852  |
| Diff = mean(female) — mean(male) |
| Ho: diff = 0  Degrees of freedom | 143 |
| Ha: diff < 0  Pr(T < t) = 0.0344 |
| Pr(T > t) = 0.0688 |
| regress hivdnacopiespermillion age c.trt c.diag c.sex c.trt#c.diag |
| Source    | SS  | df  | Prob > F | R-squared = | Adj R² = 0.0611 |
|-----------|-----|-----|----------|-------------|-----------------|
| Model     | 2,644,010.25 | 5,528,802.051 | 0.0191 |
| Residual  | 25,231,809.5 | 134,188,297.086 | 0.0948 |
| Total     | 27,875,819.7 | 139,200,545.466 | 0.196 |
| HIV DNA copies per million |
| Age       | 7.974611 | 7.111015 | 1.12 | 22.03896 | 6.089739 |
| trt       | 77.94466 | 123.3087 | −0.63 | 0.528 | −321.8278 | 165.9385 |
| Diag      | 219.8801 | 84.31013 | 2.61 | 53.1294 | 386.3609 |
| Sex       | 163.603 | 100.6832 | 1.62 | −35.53074 | 362.7368 |
| c.trt#c.diag | −191.853 | 202.5405 | −0.95 | 0.345 | −592.4428 | 208.7368 |
| _cons     | 322.6054 | 248.1464 | 1.30 | −168.185 | 813.3958 |
| estat esize, omega |
| Effect sizes for linear models |
| Source    | Omega-Squared | df | [95% Conf. Interval] |
|-----------|----------------|-----|---------------------|
| Model     | 0.0610753 | 5 | 0.136377 |
| Age       | 0.0019048 | 1 | 0.053753 |
| trt       | 0 | 1 | 0.0395842 |
| Diag      | 0.0412042 | 1 | 0.1275637 |
| Sex       | 0.0120052 | 1 | 0.0798124 |
| c.trt#c.diag | 0 | 1 | 0.051502 |
Discussion

This study demonstrated a significant correspondence between peripheral blood lymphocyte HIV-1 DNA load and neurocognitive impairment in adults with HIV-1 subtype C infection. This is the first study in South Africa to describe positive correlation between the monocyte-depleted fraction of peripheral blood lymphocytes and neurocognitive impairment in predominantly cART naïve HIV-1 clade C-infected participants. Peripheral blood lymphocytes, primarily the CD4+ subset, are the predominant cell type harboring HIV-1 in the blood of infected individuals (Schnittman et al. 1989; McBreen et al. 2001; Murray et al. 2014). The association of this major peripheral reservoir of HIV-1 DNA with neurocognitive impairment has significant pathological and clinical implications, particularly in the diagnosis and monitoring of the disease. Proviral DNA can be used to understand progression of HIV-associated neurocognitive impairment, particularly in subtle forms of the disease where symptomatic monitoring is difficult (Ruhanya et al. 2017). Theoretically, HIV in these cells can be targeted when devising therapeutic strategies to HIV-associated neurocognitive impairment. Infected CD4+ T lymphocytes are thought to transfect other cells, like CD8+ lymphocytes and monocytes, during the initial immune response (Gibellini et al. 2008; McBreen et al. 2001). Therefore, eradication of this reservoir might prevent the infection of peripheral monocytes, which are known to traffic HIV-1 into the brain. Infected macrophages in the brain are key factors in the development of HIV-associated neurocognitive disorders (Sasse et al. 2012).

Although the treated participants had lower lymphocyte HIV-1 proviral DNA reservoirs than treatment naïve patients, this was neither significant nor associated with improved neurocognitive performance. Previous studies found no significant reduction in proviral HIV DNA at pre- and 3-month post-treatment (Shikuma et al. 2012). Depending on the duration of cART, other findings have shown improvement in neurocognitive performance in adults on cART (Shikuma et al. 2012), but the introduction of cART has not fully eradicated neurological symptoms. Therefore, longitudinal studies are needed to examine how the reduction of peripheral lymphocyte HIV-1 DNA by cART correlates with neurocognitive performance in individuals over time. In this study, participants initiated treatment in the preceding 4 weeks; hence, the time to observe both the reduction of peripheral HIV-1 DNA and improvement in cognitive function was probably too short. It has been observed that significant reduction in peripheral HIV-1 DNA is dependent on early initiation of cART, which was not the case in this generally immunocompromised cohort (Gianella et al. 2011; Gannon et al. 2011; Watanabe et al. 2011; Herout et al. 2016).

We used a highly sensitive real-time qPCR, which is suitable for detection of very low copies (Malmati et al. 2008). It is also suitable for quantifying proviral DNA found in a relatively large amount of genomic DNA in the sample, which could interfere with detection of HIV-1 DNA. Our normalizer, CCR5 DNA copies were not different between impaired and unimpaired participants which is expected of a good normalizer (Nguewa et al. 2008). An appropriate normalizer enables true estimation of cells in the samples and accurate quantification of proviral HIV-1 DNA per sample, which reflect the quantity of the HIV reservoir, and does not vary between diseased and healthy patients.

Previous investigations have shown that total HIV-1 proviral DNA in PBMC subsets differed significantly between mild and severe forms of neurocognitive impairment, which show a gradation from very low quantities in asymptomatic to significantly higher quantities in severe forms (Valcour et al. 2013). Therefore, with regard to lymphocytes, additional studies are needed to evaluate the effects of the HIV-1 reservoir and the severity of neurocognitive impairment so that its utility as a biomarker in different stages of the disease is tested. To further strengthen the potential of lymphocyte HIV DNA role in the pathogenesis of HAND, there is also a need for association studies between lymphocyte proviral DNA quantity and biomarkers of neuronal injury and glial dysfunction (Valcour et al. 2013).

Comparison between cognitively impaired and normal participants showed that there was no statistical difference in the quantities of both CD4+ absolute count and plasma viral load. Therefore, in this study, the standard clinical markers used in routine diagnosis and clinical monitoring of HIV did not differentiate the two groups on the basis of global deficit scores. Previous studies have also demonstrated that viral load and CD4+ count are insensitive markers of HIV-1-associated disease (Clifford and Ances 2013). Levels of these two standard markers of HIV-1 infection observed in this study are in the same ranges with quantities observed in cART-naïve patients where CD4+ counts were low and plasma viral loads were relatively high (Valcour et al. 2010; Sánchez-Ramón et al. 2003).
Although the GDS construct of HAND is important, numerous published studies demonstrated that there is considerable heterogeneity in the pattern of cognitive impairment in people with HIV. We did a further analysis using domain-specific associations such as learning, mental control, recall, and others that are used to calculate GDS to assess the effect proviral HIV-1 DNA in relation to cognitive impairment. We found that Hopkins verbal learning test score (hvlt learning) and Wechsler Adult intelligence scale (WAIS III symbol search) were very significantly reduced with increased proviral HIV-1 DNA when adjusted for sex, age, and treatment status. This study demonstrates for the first time that monocyte-depleted lymphocyte proviral HIV-1 DNA levels in subtype C patients is associated with neurocognitive status and specific neurocognitive domains in South Africa. We hypothesize that monocyte-depleted (CD14-) lymphocytes could be an important cellular subset housing the HIV-1 DNA and play a role in global and domain-specific neurocognitive impairment. These findings also suggest differential involvement of HIV-1 DNA in some regions of the CNS that may be leading to some cognitive domains being affected more than others.

### Conclusions

Our study showed that the burden of HIV-1 peripheral blood lymphocyte proviral DNA corresponds to neurocognitive

---

**Table 3** The effect of proviral HIV-1 DNA on cognitive subdomains

| regress hvltlearning hivdnacopiespermillion age ib0.treated ib1.Male | hvltlearning Coef. | Std. Err. | t | P> t | [95% Conf. Interval] |
|---|---|---|---|---|---|
| hivdnacopiespermillion | -0.0006601 | 0.0003314 | -1.99 | 0.049 | -0.0013159 - 4.34e-06 |
| Age | 0.0178903 | 0.0279508 | 0.64 | 0.523 | -0.0374236 0.0732041 |
| Treated | 0.0188188 | 0.3955738 | 0.05 | 0.962 | -0.7639389 0.8015765 |
| Male | -0.2521731 | 0.3997102 | -0.63 | 0.529 | -1.043188 0.5388416 |
| _cons | 3.152604 | 0.9872715 | 3.19 | 0.002 | 1.198823 5.106385 |

| regress hvltrecall hivdnacopiespermillion age ib0.treated ib1.Male | hvltrecall Coef. | Std. Err. | t | P> t | [95% Conf. Interval] |
|---|---|---|---|---|---|
| hivdnacopiespermillion | -0.000786 | 0.0003986 | -1.97 | 0.051 | -0.0015747 2.75e-06 |
| Age | 0.0107152 | 0.0336163 | 0.32 | 0.750 | -0.0374236 0.0732041 |
| Treated | -0.3670706 | 0.4757116 | -0.77 | 0.442 | -1.30849 0.5744387 |
| Male | 0.0651162 | 0.4807297 | 0.14 | 0.892 | -0.8862338 1.016466 |
| _cons | 7.304685 | 1.187387 | 6.15 | 0.000 | 4.954881 9.65449 |

| regress wmsmentalcontrol hivdnacopiespermillion age ib0.treated ib1.Male | wmsmentalcontrol Coef. | Std. Err. | t | P> t | [95% Conf. Interval] |
|---|---|---|---|---|---|
| hivdnacopiespermillion | -0.0020123 | 0.0011596 | -1.74 | 0.085 | -0.0043071 0.0002826 |
| Age | 0.0521593 | 0.0978096 | -0.53 | 0.595 | -0.2457216 0.141403 |
| Treated | -0.1953722 | 1.384124 | -0.14 | 0.888 | -2.934512 2.543768 |
| Male | -3.851276 | 1.398724 | -2.75 | 0.007 | -6.619311 1.083242 |
| _cons | 3.454805 | 8.37 | 0.000 | 22.08527 35.755918 |

| regress waisiidigitsymbol hivdnacopiespermillion age ib0.treated ib1.Male | waisiidigitsymbol Coef. | Std. Err. | t | P> t | [95% Conf. Interval] |
|---|---|---|---|---|---|
| hivdnacopiespermillion | -0.0023023 | 0.0025599 | -0.90 | 0.370 | -0.0073683 0.0027636 |
| Age | 0.0760948 | 0.215916 | 0.35 | 0.725 | -0.3511966 0.5033681 |
| Treated | -1.97488 | 3.055471 | -0.65 | 0.519 | -8.021569 4.071808 |
| Male | -8.138507 | 3.087703 | -2.64 | 0.009 | -14.24898 2.028034 |
| _cons | 38.19324 | 7.055488 | 5.41 | 0.000 | 24.23063 52.15584 |

| regress waisiosymbolsearch hivdnacopiespermillion age ib0.treated ib1.Male | waisiosymbolsearch Coef. | Std. Err. | t | P> t | [95% Conf. Interval] |
|---|---|---|---|---|---|
| hivdnacopiespermillion | -0.0025437 | 0.001191 | -2.14 | 0.035 | -0.0049007 -0.0001868 |
| Age | -0.0048388 | 0.1004548 | -0.05 | 0.962 | -0.2036359 0.1939583 |
| Treated | -1.049958 | 1.421557 | -0.74 | 0.462 | -3.863176 1.763261 |
| Male | -3.101115 | 1.436552 | -2.16 | 0.033 | -5.944009 -0.2582203 |
| _cons | 21.3853 | 3.282562 | 6.51 | 0.000 | 14.8892 27.88139 |
impairment among individuals infected with clade C disease. Therefore, therapeutic strategies to reduce the HIV-1 proviral DNA reservoir in lymphocytes may improve neurocognitive outcomes in PLWH.

Acknowledgments We gratefully acknowledge the Stellenbosch University Division of virology research team for reception sorting and archiving the blood samples for this study.

Funding information This study was funded by the Poliomyelitis Research Foundation (PRF), National Research Foundation (NRF) and the South African Medical Research Council (SAMRC) Collaborating Centre for HIV-1 Laboratory Research.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Benedict RH, Schretlen D, Groninger L, Dobraski M, Shpritz B (1996) Revision of the brief visuospatial memory test: studies of normal performance, reliability, and validity. Psychol Assess 8:145–153
Carroll A, Brew B (2017) HIV-1-associated neurocognitive disorders: recent advances in pathogenesis, biomarkers, and treatment. F1000Research 6(F1000 Faculty Rev):312
Cysique LA, Hey-Cunningham WJ, Dermody N, Chan P, Brew BJ, Koelsch KK (2015) Peripheral blood mononuclear cells HIV-1 DNA levels impact intermittently on neurocognition. PLoS One 10:e0120488. https://doi.org/10.1371/journal.pone.0120488
Gannon P, Muhammad Z, Kolso K, Kolso DL (2011) Current understanding of HIV-1-associated neurocognitive disorders pathogenesis. Curr Opin Neural 24:275–283
Gianella S, Wyl V, Fischer M, Niederoest B, Battegay M, Bernasconi E, Cavassini M, Rauch A, Hirschel B (2011) Effect of early antiretroviral therapy primary HIV-infection on cell-associated HIV-1DNA and plasma HIV-infection. Antivir Ther 16:535–545
Gibellini D, Borderi M, De Crignis E, Cicaola R, Cimatti L, Vitone F, Chiodo F, Re MC (2008) HIV-1DNA in peripheral blood mononuclear cells and lymphocytes from naïve and HAART-treated individuals. J Inf Secur 56:219–225
Heaps-Woodruff JM, Joska J, Cabeen R, Baker LM, Salminen LE, Hoare J, Laidlaw DH, Wamser-Nannya R, Peng CZ, Engelbrecht S, Seedat S, Stein DJ, Paul RH (2017) White matter fiber bundle lengths are shorter in cART naïve HIV: an analysis of quantitative diffusion tractography in South Africa. Brain Imaging Behav 12:1229–1238. https://doi.org/10.1007/s11682-017-9769-9
Hellmuth J, Valcour V, Spudich S (2015) CNS reservoirs for HIV: implications for eradication. J Virus Erad 1:67–71
Herout S, Mandorfer M, Breitenrecker F, Reiberger T, Grabmeier-Pfistershammer K, Rieger A (2016) Impact of early initiation of antiretroviral therapy in patients with acute HIV-1 infection in Vienna, Austria. PLoS One 11:e0152910. https://doi.org/10.1371/journal.pone.0152910
Hong S, Banks WA (2015) Role of immune system in neuroinflammation and neurocognitive implications. Brain Behav Immun 45:1–12
Jumare J, Sunshine S, Ahmed H, El-Kamary SS, Magder L, Hungerford L (2017) Peripheral blood lymphocyte HIV-1 DNA levels correlate with HIV-1-associated neurocognitive disorders in Nigeria. J Neuro-Oncol 23:474–482. https://doi.org/10.1007/s13365-017-0520-5
Kamat A, Misra V, Cassol E, Ancuta P, Yan Z (2012) A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy. PLoS One 7:e30881
Malnati MS, Scarlatti G, Gatto F, Salvator F, Cassina G, Rutigliano T, Volpi R, Lusso P (2008) A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load. Nat Protoc 37:1240–1248. https://doi.org/10.1038/nprot.2008.108
McBreen S, Imlach S, Shirafi D, Scott GR, Leen C, Bell JE, Simmonds P (2001) Infection of the CD45RA1 (naïve) subset of peripheral CD81 lymphocytes by human immunodeficiency virus type 1 in vivo. J Virol 75:4091–4102
Morgenstern JP, Land H (1990) Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 18:3587–3596
Murray JM, Zaunders JJ, McBride KL, Xu Y, Bailey M, Suzuki K, Cooper DA, Emery S, Kelleher AD, Koelsch KK (2014) HIV-1 DNA subspecies persist in both activated and resting memory CD4+–T cells during antiretroviral therapy. J Virol 88:3516–3526
Ndung’u T, Renjifo B, Essex M (2001) Construction and analysis of an infectious human immunodeficiency virus type 1 subtype C molecular clone. J Virol 75:4964–4972
Nguewa PA, Agorreta J, Blanco D, Lozano MD, Gomez-Roman J, Sanchez BA (2008) Identification of importin 8 (IPO8) as the most accurate reference gene for the clinicopathological analysis of lung specimens. BMC Mol Biol 9:103. https://doi.org/10.1186/1471-2253-9-03
Paul RH, Joska JA, Woods C, Seedat S, Engelbrecht S, Hoare J (2014) Impact of the HIV-1 tat C303CS1S dyecestine substitution on neuropsychological function in patients with clade C disease. J Neuro-Oncol 6:627–635. https://doi.org/10.1007/s11665-014-0293-z
Paul RH, Phillips S, Hoare J, Laidlaw DH, Cabeen R, Olbricht GR, Su Y (2017) Neuroimaging abnormalities in clade C HIV are independent of total genetic diversity of total genetic diversity. J Neuro-Oncol 23:319–328
Prediger E (2008) Calculations: converting from nanograms to copy number. S: //www.idtdna.com/pages/education/decoded/article/calculations-converting-from-nanograms-to-copy-number accessed 13/09/2018
Price RW, Epstein LG, Becker JT, Cinque P, Gisslen M, Pulliam L, McArthur JC (2007) Biomarkers of HIV-1 CNS infection and injury. Neurology 68:19. https://doi.org/10.1212/01.wnl.0000278457. 55877.eb
Rohany V, Jacobs GB, Glashoff RR, Engelbrecht S (2017) Clinical relevance of Total HIV-1 DNA in peripheral blood mononuclear cell compartments as a biomarker of HIV-1-associated neurocognitive disorders (HAND). Viruses 9:324. https://doi.org/10.3390/v9110324
Sánchez-Ramón S, Bellón JM, Resino S, Cantó-Nogués C, Gurbindo D, Ramos JT, Muñoz-Fernández AM (2003) Low blood CD8+ T-lymphocytes and high circulating monocytes are predictors of
HIV-1-associated progressive encephalopathy in children. Pediatrics. 111:e168–e175. https://doi.org/10.1542/peds.111.2.e168
Sasse T, Wu J, Zhou L, Saksena K (2012) Monocytes and their role in human immunodeficiency virus pathogenesis. AJDM. 8:92–105
Saylor D, Dickens AM, Sackett N, Haughey N, Slusher B, Pletnikov M, Mankowski JL, Brown A, Volsky DJ, McArthur JC (2016) HIV-1-associated neurocognitive disorder — pathogenesis and prospects for treatment. Nat Rev Neurol 12:309. https://doi.org/10.1038/nrneurol.2016.53
Schnittman SM, Psallidopoulos MC, Lane HC, Thompson L, Baseler M, Massari F, Fox CH, Salzman NP, Fauci AS (1989) The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science 245:305–308
Shikuma CM, Nakamoto B, Shiramizu B, Liang CY, DeGruttola V, Bennett K, Paul R, Kallianpur K, Chow D, Gavegnano C, Hurwitz SJ, Schinazi RF, Valcour VG (2012) Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV-1. Antivir Ther 177:1233–1242. https://doi.org/10.3851/IMP2411
Shiramizu B, William S, Shikuma CM, Valcour V (2009) Amount of HIV-1 DNA in peripheral blood mononuclear cells is proportional to the severity of HIV-1-associated neurocognitive disorders. J Neuropsychiatry Clin Neurosci 21:68–74
Valcour VG, Shiramizu BT, Shikuma CM (2010) HIV-1 DNA in circulating monocytes as a mechanism to dementia and other HIV-1 complications. JLB. 87:621–626. https://doi.org/10.1189/jlb.0809571
Valcour V, Chalermchai T, Sailsutana N (2012) Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis 206:275–282
Valcour VG, Anaworanich J, Agsalda M, Sailsutana N, Chalermchai T, Schuetz A (2013) HIV-1 DNA reservoir increases risk for cognitive disorders in cART-naive patients. PLoS One. https://doi.org/10.1371/journal.pone.0070164
Watanabe D, Ibe S, Uehira T, Minami R, Sasakawa A, Yajima K, Yonemoto H, Bando H, Ogawa Y, Taniguchi T, Kasai D, Nishida Y, Yamamoto M, Kaneda T, Shirasaka T (2011) Cellular HIV-1 DNA levels in patients receiving antiretroviral therapy strongly correlate with therapy initiation timing but not with therapy duration. BMC Infect Dis 11:146
Williams DW, Veenstra M, Gaskill PJ, Morgello S, Calderon TM, Berman JW (2014) Monocyte mediate HIV-1 neuropathogenesis: mechanisms that contribute to HIV-1-associated neurocognitive disorders. Curr HIV-1 Res 12:85–96
Yusuf AJ, Hassan A, Mamman AI, Muktar HM, Sulieman AM, Baiyewu O (2017) Prevalence of HIV-1-associated neurocognitive disorder (HAND) among patients attending a tertiary health facility in Northern Nigeria. J Int Assoc Provid AIDS Care 16:48–55. https://doi.org/10.1177/2325957414553839

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.